Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|July 14, 2015
Efficacy of Onapristone in PR-Expressing Tumors
Author(s)Alexander Zukiwski, MD
Alexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.
Advertisement
ONA was previously evaluated in women with breast cancer, and it produced positive results. Zukiwski and his team reevaluated the drug in a phase I study, believing that they solved one of its major safety issues. They recently started a phase II study in women who have recurrent and metastatic endometrial cancer.
Alexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
4
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
5